As of June 9, 2020,
a U.S. patent (10/675,294) for a pharmaceutique composition for the treatment of lésions cornéennes containing 8-oxo-2'-deoxyguanosine or a pharmaceutiquely acceptable salt thereof as an active ingredient
has been registered, and we are pleased to announce this achievement. Sur la base de this patent, RudaCure is simultaneously pursuing U.S. essais cliniques and preparing for its U.S. entrée sur le marché.